Beta Drugs Q2 & H1 FY27: Revenue Up 29.2%, PAT Grows 45%
Beta Drugs reported a 29.2% revenue increase for H1 FY27 and a 45% PAT growth to ₹34 crores. EBITDA margins improved to 23.18%. The company expects 20-25% annual growth for the next 3-5 years with sustained 23-24% margins. Exports and the Nivian acquisition are key growth drivers.
The announcement includes significant financial performance metrics, clear growth guidance for the medium term, and strategic initiatives like acquisitions and expansion into new markets, which are material to investors.
The company reported strong financial growth in revenue and profit, along with positive commentary on future growth prospects and margin expansion. The negligible impact of trade margin capping and successful integration of acquisitions also contribute to the positive sentiment.
Beta Drugs Limited announced its financial results for the second quarter (Q2) and the first half (H1) of the fiscal year 2027 (FY27) on October 22, 2026. The company reported a robust revenue growth of 29.2% for H1 FY27 compared to H1 FY26. EBITDA margins saw a slight improvement, increasing by 0.10% to 23.18% from 23.08%. Profit After Tax (PAT) demonstrated significant growth, rising by approximately 45% from ₹24 crores in H1 FY26 to ₹34 crores in H1 FY27.
The company also addressed the impact of trade margin capping on MRPs, stating that the overall impact on Beta Drugs is negligible. For H1 FY27, the own-branded business grew by 17%. In exports, 76 new dossiers were filed across various geographies, including four in Europe, with bioequivalence studies underway for five products in regulated markets.
Beta Drugs successfully launched four new products in FY27 and plans to launch six more. Five brands have achieved sales exceeding ₹5 crores, with one nearing ₹10 crores in annual sales. The company secured a breakthrough with Tata Hospital, getting several brands approved. The recent acquisition, Nivian Lifesciences, showed strong growth of 75% in H1 FY27, and the API business grew by 30%.
Looking ahead, Beta Drugs aims to deliver 20-25% growth over the next three to five years with sustained EBITDA margins of 23-24%. The company is also evaluating opportunities in the biosimilar market and considering manufacturing oncology medicines outside India in focus geographies.
What to do with a filing like this
Beta Drugs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Beta Drugs Limited. Read the original for the full detail.